Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HBM Holdings Limited (HBMHF)
Shanghai, CN
HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human anti-CTLA-4 antibody directed against cytotoxic T-lymphocyte-associated antigen-4. Furthermore, HBM is advancing HBM9022 as a treatment for SARS-COV-2, HBM9302 for breast and gastric cancers, and HBM7020 for multiple myeloma. A diverse array of other compounds, such as HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022, are also under development for various solid tumors. HBM Holdings maintains a global operational footprint, spanning Mainland China, the United States, Europe, and other international territories. The company has established strategic partnerships for antibody-drug conjugate (ADC) initiatives with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. Incorporated in 2016, HBM Holdings Limited's corporate headquarters are located in Shanghai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -38.10% | -38.10% | +41.82% | +223.65% | +227.11% | +227.11% | +227.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+315.3% ★ Q4'25: +16.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+2,955.6% ★ Q4'25: -22.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+53.7% ★ Q4'25: +14.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+51.0% ★ Q4'25: +21.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+169.3% ★ Q4'25: +101.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+5.0% Q4'25: +26.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.98× ★ Q4'25: 1.48× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.11M
est: 11.22M (+25.8%)
|
4.29M
est: 9.65M (-55.5%)
|
40.76M
est: 44.70M (-8.8%)
|
89.50M
est: 105.00M (-14.8%)
|
38.10M
est: 35.70M (+6.7%)
|
158.21M
est: 188.12M (-15.9%)
|
230.28M
222.30M – 238.26M
+22.4% YoY
|
231.24M
215.26M – 247.22M
+0.4% YoY
|
258.41M
249.46M – 267.36M
+11.7% YoY
|
200.00M
193.07M – 206.93M
-22.6% YoY
|
238.00M
229.76M – 246.24M
+19.0% YoY
|
| EBITDA |
-290.81M
est: -5.35M (-5,338.2%)
|
-130.84M
est: -4.60M (-2,745.3%)
|
-127.30M
est: -21.31M (-497.3%)
|
31.26M
est: -50.06M (+162.4%)
|
10.17M
est: -6.12M (+266.1%)
|
83.23M
est: -32.27M (+357.9%)
|
-39.50M
-40.87M – -38.14M
-22.4% YoY
|
-39.67M
-42.41M – -36.93M
-0.4% YoY
|
-44.33M
-45.87M – -42.79M
-11.7% YoY
|
-34.31M
-35.50M – -33.12M
+22.6% YoY
|
-40.83M
-42.24M – -39.41M
-19.0% YoY
|
| EBIT |
-296.44M
est: -5.63M (-5,161.9%)
|
-137.65M
est: -4.84M (-2,741.3%)
|
-135.35M
est: -22.45M (-502.9%)
|
26.55M
est: -52.74M (+150.3%)
|
7.24M
est: -7.15M (+201.3%)
|
80.70M
est: -37.67M (+314.2%)
|
-46.12M
-47.71M – -44.52M
-22.4% YoY
|
-46.31M
-49.51M – -43.11M
-0.4% YoY
|
-51.75M
-53.54M – -49.96M
-11.7% YoY
|
-40.05M
-41.44M – -38.66M
+22.6% YoY
|
-47.66M
-49.31M – -46.01M
-19.0% YoY
|
| Net Income |
-296.48M
est: -850.79M (+65.2%)
|
-137.32M
est: -124.78M (-10.1%)
|
-137.55M
est: -142.28M (+3.3%)
|
22.80M
est: 7.85M (+190.3%)
|
2.78M
est: -5.69M (+148.8%)
|
91.47M
est: 57.33M (+59.5%)
|
71.74M
68.51M – 74.97M
+25.1% YoY
|
74.00M
70.66M – 77.33M
+3.1% YoY
|
97.93M
93.52M – 102.34M
+32.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
38.60M
est: 28.45M (+35.7%)
|
38.24M
est: 24.46M (+56.3%)
|
24.91M
est: 113.37M (-78.0%)
|
20.56M
est: 266.30M (-92.3%)
|
7.55M
est: 72.29M (-89.6%)
|
28.30M
est: 380.94M (-92.6%)
|
466.30M
450.15M – 482.46M
+22.4% YoY
|
468.25M
435.89M – 500.61M
+0.4% YoY
|
523.27M
505.14M – 541.39M
+11.7% YoY
|
404.99M
390.96M – 419.01M
-22.6% YoY
|
481.93M
465.24M – 498.63M
+19.0% YoY
|
| EPS |
-0.39
est: -1.10 (+64.6%)
|
-0.19
est: -0.16 (-17.6%)
|
-0.19
est: -0.18 (-3.2%)
|
0.03
est: 0.01 (+206.0%)
|
0.00
est: -0.01 (+151.3%)
|
0.12
est: 0.07 (+69.7%)
|
0.09
0.08 – 0.09
+25.1% YoY
|
0.09
0.09 – 0.10
+3.1% YoY
|
0.12
0.12 – 0.13
+32.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jingsong Wang | Founder, Chairman & Chief Executive Officer | 1M | — |
| Yiping Rong | Chief Scientific Officer & Executive Director | 424.0K | — |
| Ian Y. Liu | Senior Vice President & Global Head of Legal and Joint Company Secretary | — | — |
| Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | — | male |
| Peter F. Moesta | Member of Scientific Advisory Board & Chief CMC Advisor | — | — |
| Raymond S. Zheng | Chief Business Officer | — | — |
| Steve Arkinstall DPhil | Chief Scientific Advisor | — | — |
| Xiaolu Tao | Chief Development Officer | — | — |
| Ben Chih | Chief Scientific Officer of Neurosciences - Harbour BioMed US | — | — |
| Youchen Chen | Vice President, Chief Financial Officer & Investor Relations | — | male |
| C. Adam Zong | President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HBMHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
